

QUICK FACTS

SURGICAL SITE INFECTIONS (SSI)

PERSISTENT COSTLY PREVENTABLE

Occur in
1-2%
of all patients
undergoing inpatient
surgery worldwide¹⁻³

Affect
MILLIONS
of patients per year
USA: 1.5 million⁴
Europe: 500,000²

Increase
ANNUAL TREATMENT COSTS

USA:
+\$3.5 - \$10 billion⁵
Europe:
+€1.5 - €19 billion⁶

PROLONG HOSPITALIZATION

USA:
+9.7 days⁵
Europe:
+6.5 days⁶

3% estimated
mortality
with SSI⁴

75% of SSI-associated deaths
are directly attributable
to the infection⁴

50%
of SSI are preventable^{1,7,9}

Specific Surgery	Overall Incidence of SSI	Incidence of SSI in High-risk Patients
Colon surgery	6.10% ¹³	13.60% ¹³
Coronary artery bypass graft	3.90% ¹⁴	13.00% ¹⁴
Caesarean section	2.90% ⁴	11.70% ⁴
Laminectomy	0.72% ¹⁵	2.30% ¹⁵
Spinal fusion	0.70% ¹⁵	4.15% ¹⁵
Hip prosthesis	0.67% ¹⁵	2.40% ¹⁵
Knee prosthesis	0.58% ¹⁵	1.60% ¹⁵

Reduce the Risk of SSI

Procellera™
ANTIMICROBIAL WOUND DRESSING
POWERED BY V.DOX™ TECHNOLOGY

Procellera kills a broad-spectrum of microbes, including multidrug-resistant and biofilm-forming bacteria¹⁰⁻¹²

vomaris.com



REFERENCES

1. Keely B, Sridhar R, Scott N. (2018). Centers for Disease Control and Prevention 2017 Guidelines for Prevention of Surgical Site Infections: Review and Relevant Recommendations. *Current Reviews in Musculoskeletal Medicine*. 2. Stop Infections After Surgery. (2016). World Health Organization. 3. Monina K, Jonathan E, Chesley R, et al. (2007). Estimating Health Care-Associated Infections and Deaths in U.S. Hospitals, 2002. *Public Health Reports*. 4. Michael P. (2017). 2017 HICPAC-CDC Guideline for Prevention of Surgical Site Infection: What the Infection Preventionist Needs to Know. *Prevention in Action*. 5. Douglas S. (2009). The Direct Medical Costs of Healthcare-Associated Infection in U.S. Hospitals and the Benefits of Prevention. Centers for Disease Control and Prevention. 6. David L, Harry V, Jacqueline R, et al. (2004). Surgical Site Infection - A European Perspective of Incidence and Economic Burden. *International Wound Journal*. 7. Surveillance of Surgical Site Infections in Europe. (2010-2011). ECDC Surveillance Report. 8. Sandra B, Craig U, Dale B, et al. (2017). Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. *JAMA Surgery*. 9. Global Guidelines for the Prevention of Surgical Site Infection. (2018). World Health Organization. 10. Kim H, Makin I, Skiba J, et al. (2014). Antibacterial Efficacy Testing of a Bioelectric Wound Dressing Against Clinical Wound Pathogens. *Open Microbiology Journal*. 11. Banerjee J, Ghatak P, Roy S, et al. (2015). Silver-Zinc Redox-Coupled Electrochemical Wound Dressing Disrupts Bacterial Biofilm. *PLoS One*. 12. Kim H, Izadjoo M. (2015). Antibiofilm Efficacy Evaluation of a Bioelectric Dressing in Mono- and Multi-Species Biofilms. *Journal of Wound Care*. 13. Ramzi A, Anne D, Hiroko K, et al. (2017). Risk Stratification for Surgical Site Infection in Colon Cancer. *JAMA Surgery*. 14. Melissa R, Julian J, Joseph G, et al. (2018). Multi-Centre Prospective Internal and External Evaluation of the Brompton Harefield Infection Score (BHIS). *Journal of Infection Prevention*. 15. Guide to the Elimination of Orthopedic Surgical Site Infections. (2010). An Apic Guide.

Please review the Instructions for Use for a complete list of indications, contraindications, warnings, and precautions.

© 2022 Vomaris. All rights reserved. Vomaris logo, Vomaris, Procellera, and V.Dox are trademarks of Vomaris Innovations, Inc.

K-91 Rev. D

Vomaris Wound Care, Inc.

1911 East Fifth Street | Tempe, AZ 85288 USA

+1 (480) 921-4948 | (866) 496-8743

vomaris.com

